Loading
A planned MD Anderson trial of helper T cells against the NY-ESO-1 protein, given with the immunotherapy drug ipilimumab, for melanoma and sarcoma. It was withdrawn before anyone joined.
The registry describes a phase I study of autologous CD4+ NY-ESO-1-specific T cells with anti-CTLA-4 (ipilimumab) and cyclophosphamide for patients with NY-ESO-1-expressing tumours, listing melanoma and sarcoma as conditions (ClinicalTrials.gov NCT02210104). It was withdrawn with an actual enrolment of 0; the reason given is "Issues with tetramer staining" (ClinicalTrials.gov NCT02210104). Cassian Yee is listed as principal investigator; the record names NIH grant R01CA104711 (ClinicalTrials.gov NCT02210104).
Shares MD Anderson Cancer Center and the tag failure.
Shares Melanoma and the tag failure.
Shares Melanoma and the tag failure.
Shares Melanoma and the tag failure.
Shares Melanoma and the tag failure.
Shares Melanoma and the tag failure.
Shares CTAG1B, Endogenous T-cell therapy, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Cassian Yee, Cyclophosphamide, National Cancer Institute (NIH).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/